Literature DB >> 23471749

The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia.

Zhi L Teo1, Sarah D Sawyer, Paul A James, Gillian Mitchell, Alison H Trainer, Geoffrey J Lindeman, Kylie Shackleton, Linda Cicciarelli, Melissa C Southey.   

Abstract

The familial aggregation of breast cancer has been well-described with approximately 25% of breast cancers attributable to inherited mutations in currently known breast cancer susceptibility genes. PALB2 c.3113G>A (p.Trp1038*) is a protein-truncating mutation which has been associated with high estimated risk of breast cancer in Australian women (91%; 95% CI = 44-100) to age 70 years. This study screened for PALB2 c.3113G>A in germline DNA representing 871 unrelated individuals from "high-risk" breast and/or ovarian cancer families evaluated in the setting of a Familial Cancer Centre in Australia. The PALB2 c.3113G>A mutation was identified in eight of 871 probands (0.92%) from these families. Median age of diagnosis was 42 years. Five of these eight women had contra-lateral breast cancers. Available data suggests that PALB2 c.3113G>A is a rare mutation with estimated breast cancer risks similar in magnitude to that associated with BRCA2 mutations. Although the proportion of high-risk women carrying this PALB2 mutation is low, research efforts should continue in order to effect its translation into clinical genetic testing practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23471749     DOI: 10.1007/s10689-013-9620-4

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  28 in total

Review 1.  Pathological prognostic factors in breast cancer.

Authors:  C W Elston; I O Ellis; S E Pinder
Journal:  Crit Rev Oncol Hematol       Date:  1999-08       Impact factor: 6.312

2.  Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Authors:  Hanne Meijers-Heijboer; Ans van den Ouweland; Jan Klijn; Marijke Wasielewski; Anja de Snoo; Rogier Oldenburg; Antoinette Hollestelle; Mark Houben; Ellen Crepin; Monique van Veghel-Plandsoen; Fons Elstrodt; Cornelia van Duijn; Carina Bartels; Carel Meijers; Mieke Schutte; Lesley McGuffog; Deborah Thompson; Douglas Easton; Nayanta Sodha; Sheila Seal; Rita Barfoot; Jon Mangion; Jenny Chang-Claude; Diana Eccles; Rosalind Eeles; D Gareth Evans; Richard Houlston; Victoria Murday; Steven Narod; Tamara Peretz; Julian Peto; Catherine Phelan; Hong Xiang Zhang; Csilla Szabo; Peter Devilee; David Goldgar; P Andrew Futreal; Katherine L Nathanson; Barbara Weber; Nazneen Rahman; Michael R Stratton
Journal:  Nat Genet       Date:  2002-04-22       Impact factor: 38.330

Review 3.  Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease.

Authors: 
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

4.  Influence of a family history of cancer within and across multiple sites on patterns of cancer mortality risk for women.

Authors:  C A Poole; T Byers; E E Calle; J Bondy; P Fain; C Rodriguez
Journal:  Am J Epidemiol       Date:  1999-03-01       Impact factor: 4.897

5.  Breast cancer family history as a risk factor for early onset breast cancer.

Authors:  H T Lynch; P Watson; T Conway; M L Fitzsimmons; J Lynch
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

6.  A role for common genomic variants in the assessment of familial breast cancer.

Authors:  Sarah Sawyer; Gillian Mitchell; Joanne McKinley; Georgia Chenevix-Trench; Jonathan Beesley; Xiao Qing Chen; David Bowtell; Alison H Trainer; Marion Harris; Geoffrey J Lindeman; Paul A James
Journal:  J Clin Oncol       Date:  2012-10-29       Impact factor: 44.544

7.  Risk factors for breast cancer according to family history of breast cancer. For the Nurses' Health Study Research Group.

Authors:  G A Colditz; B A Rosner; F E Speizer
Journal:  J Natl Cancer Inst       Date:  1996-03-20       Impact factor: 13.506

8.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.

Authors:  Sheila Seal; Deborah Thompson; Anthony Renwick; Anna Elliott; Patrick Kelly; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Munaza Ahmed; Katarina Spanova; Bernard North; Lesley McGuffog; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Journal:  Nat Genet       Date:  2006-10-08       Impact factor: 38.330

9.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

10.  Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.

Authors:  T S Frank; A M Deffenbaugh; M Hulick; K Gumpper
Journal:  Dis Markers       Date:  1999-10       Impact factor: 3.434

View more
  6 in total

1.  Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from Central and Eastern Europe.

Authors:  Monika Noskowicz; Natalia Bogdanova; Marina Bermisheva; Zalina Takhirova; Natalia Antonenkova; Elza Khusnutdinova; Michael Bremer; Hans Christiansen; Tjoung-Won Park-Simon; Peter Hillemanns; Thilo Dörk
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

2.  Association of PALB2 sequence variants with the risk of familial and early-onset breast cancer in a South-American population.

Authors:  Yessica Leyton; Patricio Gonzalez-Hormazabal; Rafael Blanco; Teresa Bravo; Ricardo Fernandez-Ramires; Sebastian Morales; Natalia Landeros; Jose M Reyes; Octavio Peralta; Julio C Tapia; Fernando Gomez; Enrique Waugh; Gladys Ibañez; Janara Pakomio; Gilberto Grau; Lilian Jara
Journal:  BMC Cancer       Date:  2015-01-31       Impact factor: 4.430

3.  PALB2 and breast cancer: ready for clinical translation!

Authors:  Melissa C Southey; Zhi L Teo; Ingrid Winship
Journal:  Appl Clin Genet       Date:  2013-07-19

4.  Tumour morphology predicts PALB2 germline mutation status.

Authors:  Z L Teo; E Provenzano; G S Dite; D J Park; C Apicella; S D Sawyer; P A James; G Mitchell; A H Trainer; G J Lindeman; K Shackleton; L Cicciarelli; S S Buys; I L Andrulis; A M Mulligan; G Glendon; E M John; M B Terry; M Daly; F A Odefrey; T Nguyen-Dumont; G G Giles; J G Dowty; I Winship; D E Goldgar; J L Hopper; M C Southey
Journal:  Br J Cancer       Date:  2013-06-20       Impact factor: 7.640

5.  Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada.

Authors:  Taila Hartley; Luca Cavallone; Nelly Sabbaghian; Rachel Silva-Smith; Nancy Hamel; Olga Aleynikova; Erika Smith; Valerie Hastings; Pedro Pinto; Marc Tischkowitz; Eva Tomiak; William D Foulkes
Journal:  Hered Cancer Clin Pract       Date:  2014-08-28       Impact factor: 2.857

Review 6.  PALB2: research reaching to clinical outcomes for women with breast cancer.

Authors:  Melissa C Southey; Ingrid Winship; Tú Nguyen-Dumont
Journal:  Hered Cancer Clin Pract       Date:  2016-04-19       Impact factor: 2.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.